Sweet genetics

The limited information regarding molecular targets and genetic factors in current treatments for type 2 diabetes (T2D) hampers doctors’ and researchers’ ability to predict response and adverse effects in patients. Using data from a clinical study called SUGAR-MGH, CGM faculty members, Jose Florez and Miriam Udler, and colleagues investigated how genetic variations affect the response to the glucose-lowering medications, glipizide and metformin, in individuals with T2D. After genotyping 1,000 participants (at risk for developing T2D) from diverse ancestries in the study, the team discovered new variations related to the effectiveness of these medications and gained insights into the underlying mechanisms of T2D.

Read more in Diabetologia.

June 21, 2023


CGM Primary Investigators

Jose Florez

Miriam Udler